Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Blood (2023) 142 (Supplement 1): 5480.

https://doi.org/10.1182/blood-2023-181299

Published: 2023

Journal Articles

Chronic Disease Outcomes As Predictors of Quality of Life in Patients with Hemophilia Α: Data from the Real-World AHEAD International Study

Margareth Castro Ozelo, Sarah Brighton, Enrico Ferri Grazzi, Cedric Hermans, Randy Guerra, Joan Gu, Pooja Oberai

Blood (2023) 142 (Supplement 1): 5511.

https://doi.org/10.1182/blood-2023-188874

Published: 2023

Journal Articles

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Amy L. Dunn, Yesim Dargaud, Yasmina L. Abajas, Manuel Carcao, Giancarlo Castaman, Adam Giermasz, Cédric Hermans, Magdalena D. Lewandowska, Johnny Mahlangu, Shannon L. Meeks, Wolfgang A. Miesbach, Michael Recht, Vanessa Salinas, Tammuella Chrisentery-Singleton, Hongying Wang, Ian S Mitchell, Guy Young

Blood (2022) 140 (Supplement 1): 8485–8488.

https://doi.org/10.1182/blood-2022-157343

Published: 2022

Journal Articles

Perioperative Monitoring with Global Coagulation Test in Severe Hemophilia a without Inhibitor on Emicizumab Prophylaxis Undergoing Orthopedic Surgery

Abel Dos Santos Ortas, Jose Manuel Martin de Bustamante Gonzalez-Iglesias, Maria Isabel Perez Vaquero, Maria Teresa Alvarez Roman, María Isabel Rivas Pollmar, Mónica Martín Salces, Eduardo Garcia Perez, Mar Gutierrez, Elena G Arias-Salgado, Nora V. Butta, Paula Acuña, Elena Monzón Manzano, Cédric Hermans, Víctor Jiménez-Yuste

Blood (2022) 140 (Supplement 1): 11302–11303.

https://doi.org/10.1182/blood-2022-167315

Published: 2022

Journal Articles

Predictive Value of Platelet Sequestration Studies in Splenectomy Response

Ana Mendoza, Nora V. Butta, Elena Monzón Manzano, Paula Acuña, Elena G Arias-Salgado, María Isabel Rivas Pollmar, Mónica Martín Salces, Mar Gutierrez, Eduardo Garcia Perez, Andres Ramirez Lopez, Leticia Gómez Serrano, Jose Manuel Martin de Bustamante Gonzalez-Iglesias, Barbara Martínez de Miguel, Elena Martínez Montalbán, Elena Dobra, Cédric Hermans, Víctor Jiménez-Yuste, María Teresa Alvarez Román

Blood (2022) 140 (Supplement 1): 2649–2651.

https://doi.org/10.1182/blood-2022-156930

Published: 2022

Journal Articles

Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid

Andres Ramirez Lopez, María Teresa Alvarez Román, María Isabel Rivas Pollmar, Mónica Martín Salces, Mar Gutierrez, Eduardo Garcia Perez, Elena G Arias-Salgado, Elena Monzón Manzano, Paula Acuña, Víctor Jiménez Yuste, Nora V. Butta, Cédric Hermans

Blood (2022) 140 (Supplement 1): 2676–2677.

https://doi.org/10.1182/blood-2022-158266

Published: 2022

Journal Articles

Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor

María Isabel Rivas Pollmar, Elena G Arias-Salgado, María Teresa Alvarez Román, Elena Monzón Manzano, Paula Acuña, Mónica Martín Salces, Sara García Barcenilla, Nora V. Butta, Cédric Hermans, Víctor Jiménez-Yuste

Blood (2022) 140 (Supplement 1): 8462–8463.

https://doi.org/10.1182/blood-2022-170037

Published: 2022

Journal Articles

Relationship between Molecular Profile and Platelet Function and Thrombin Generation in Patients with Essential Thrombocytemia

Mercedes Gasior Kabat, Elena Monzón Manzano, Paula Acuña, María Teresa Alvarez Román, Elena G Arias-Salgado, María Isabel Rivas Pollmar, Matias Facal Giuliani, Patricia Gonzalez Marugan, Sara García Barcenilla, Fernando Gomez Aguado, Concepción Ramos Castro, Cédric Hermans, Víctor Jiménez Yuste, Nora V. Butta

Blood (2022) 140 (Supplement 1): 12266–12267.

https://doi.org/10.1182/blood-2022-167776

Published: 2022

Journal Articles

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Blood (2021) 138 (Supplement 1): 3195.

https://doi.org/10.1182/blood-2021-147434

Published: 2021

Journal Articles

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

Claude Négrier, Johnny Mahlangu, Michaela Lehle, Pratima Chowdary, Olivier Catalani, Víctor Jiménez-Yuste, Benjamin M. Beckermann, Christophe Schmitt, Cedric Hermans, Giuliana Ventriglia, Jerzy Windyga, Anna Kiialainen, Roseline d'Oiron, Paul Moorehead, Vanda Teodoro, Amy D. Shapiro, Johannes Oldenburg

Blood (2021) 138 (Supplement 1): 343.

https://doi.org/10.1182/blood-2021-146009

Published: 2021

Journal Articles

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Steven W. Pipe, MD, Michael Recht, MD PhD, Nigel S. Key, MD, Frank W.G. Leebeek, MD PhD, Giancarlo Castaman, MD, Susan U. Lattimore, R.N., Paul Van Der Valk, Kathelijne Peerlinck, MD PhD, Michiel Coppens, MD, Niamh O'Connell, MD PhD, John Pasi, MB, ChB, PhD FRCP, FRCPath, FRCPCH, Peter Kampmann, MD, Karina Meijer, MD PhD, Annette von Drygalski, MD Pharm D, Guy Young, MD, Cedric Hermans, MDMRCP,PhD, Jan Astermark, MD PhD, Robert Klamroth, MD PhD, Richard S. Lemons, MD, Nathan Visweshwar, MD, Shelley Crary, MD MS, Rashid Kazmi, MBBS, Emily Symington, Miguel A. Escobar, MD, Esteban Gomez, MD, Rebecca Kruse-Jarres, MD, Adam Kotowski, MD, Doris Quon, MD PhD, Michael Wang, MD, Allison P. Wheeler, MD, Eileen K Sawyer, PhD, Stephanie Verweij, BSc, Valerie Colletta, MSc, Naghmana Bajma, MD, Robert Gut, MD PhD, Wolfgang A. Miesbach, MD PhD

Blood (2020) 136 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2020-143560

Published: 2020

Journal Articles

Potential Usefulness of D-Dimers Assay in Treated Patients with FVIII Deficiency to Detect a Prothrombotic State

Cedric Hermans, MDMRCP,PhD, Catherine Lambert, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-137517

Published: 2020

Journal Articles

Real-World Clinical Management of Patients with Congenital Hemophilia and Inhibitors: Interim Analysis of the FEIBA Global Outcome Study (FEIBA GO)

Cedric Hermans, MDMRCP,PhD, Claude Négrier, Pål A Holme, Carmen Escuriola, Ana R Cid, Nataliya Kemenyash, MSc, Jaco Botha, Viridiana Cano-Garcia, Jerzy Windyga

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139298

Published: 2020

Journal Articles

Problem Joints and Their Clinical and Humanistic Burden in Children and Adults with Moderate and Severe Hemophilia a: CHESS Paediatrics and CHESS II

Paul McLaughlin, MSc, MMACP, Cedric Hermans, MDMRCP,PhD, Sohaib Asghar, Tom Burke, Francis Nissen, Martynas Aizenas, Oliver Meier, Harpal Dhillon, Jamie O'Hara, MSc

Blood (2020) 136 (Supplement 1): 33–34.

https://doi.org/10.1182/blood-2020-140306

Published: 2020

Journal Articles

Single 225μg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia Α or Β with Inhibitors: A PERSEPT1 Subset Analysis

Janna M. Journeycake, MD, Cedric Hermans, MDMRCP,PhD, Jonathan M. Ducore, MD MPH, Miguel A. Escobar, MD, Guy Young, MD, Michael Wang, MD, Doris Quon, MD PhD, W Allan Alexander, MD, Ian S Mitchell, PhD, Ahmad Al-Sabbagh, MD, Daniel Bonzo, PhD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-136443

Published: 2020

Journal Articles

In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors

Steven W. Pipe, MD, Michael Recht, MD PhD, Michael U. Callaghan, MD, Robert F. Sidonio, Jr., MDMSc, Jerry Grandoni, PhD, Veronique Duretz, Daniel Bonzo, PhD, Jean Luc Plantier, PhD, Sean Evans, PhD RPh, Ian S Mitchell, PhD, Cedric Hermans, MDMRCP,PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-136430

Published: 2020

Journal Articles

PERSEPT3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia Α or B with Inhibitors

Miguel A. Escobar, MD, Doris Quon, MD PhD, Cindy A. Leissinger, MD, James V Luck, Jr., MD, Ahmad Al-Sabbagh, MD, Daniel Bonzo, PhD, Ian S Mitchell, PhD, W Allan Alexander, MD, Cedric Hermans, MDMRCP,PhD

Blood (2020) 136 (Supplement 1): 34–36.

https://doi.org/10.1182/blood-2020-136448

Published: 2020

Journal Articles

Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data

Wolfgang A. Miesbach, Giovanni Di Minno, Elena Santagostino, Dr. Klamroth, Inga Bayh, Amaryllis Soto, Cedric Hermans

Blood (2019) 134 (Supplement_1): 1117.

https://doi.org/10.1182/blood-2019-128486

Published: 2019

Journal Articles

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

Corien L. Eckhardt, Alice S. van Velzen, Marjolein Peters, Jan Astermark, Paul P. Brons, Giancarlo Castaman, Marjon H. Cnossen, Natasja Dors, Carmen Escuriola-Ettingshausen, Karly Hamulyak, Daniel P. Hart, Charles R. M. Hay, Saturnino Haya, Waander L. van Heerde, Cedric Hermans, Margareta Holmström, Victor Jimenez-Yuste, Russell D. Keenan, Robert Klamroth, Britta A. P. Laros-van Gorkom, Frank W. G. Leebeek, Ri Liesner, Anne Mäkipernaa, Christoph Male, Evelien Mauser-Bunschoten, Maria G. Mazzucconi, Simon McRae, Karina Meijer, Michael Mitchell, Massimo Morfini, Marten Nijziel, Johannes Oldenburg, Kathelijne Peerlinck, Pia Petrini, Helena Platokouki, Sylvia E. Reitter-Pfoertner, Elena Santagostino, Piercarla Schinco, Frans J. Smiers, Berthold Siegmund, Annarita Tagliaferri, Thynn T. Yee, Pieter Willem Kamphuisen, Johanna G. van der Bom, Karin Fijnvandraat

Blood (2013) 122 (11): 1954–1962.

https://doi.org/10.1182/blood-2013-02-483263

Published: 2013

Includes: Supplemental data

Journal Articles

GPVI Mutation and Absent Platelet Collagen Activation in a Patient with a Bleeding Disorder.

Kathleen Freson, PhD, Cedric Hermans, MD, PhD, Chantal Thys, Christel Van Geet, MD, PhD

Blood (2007) 110 (11): 2106.

https://doi.org/10.1182/blood.V110.11.2106.2106

Published: 2007

NARROW

Low Rebleed Incidence with Eptacog Beta Treatment through 24 and 48 Hours in Children (<12 years) with Hemophilia a or B with Inhibitors

Chronic Disease Outcomes As Predictors of Quality of Life in Patients with Hemophilia Α: Data from the Real-World AHEAD International Study

Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Perioperative Monitoring with Global Coagulation Test in Severe Hemophilia a without Inhibitor on Emicizumab Prophylaxis Undergoing Orthopedic Surgery

Predictive Value of Platelet Sequestration Studies in Splenectomy Response

Discontinuation of Thrombopoietin Receptor Agonists: A 10 Year Real-World Experience from an Academic Hospital in Madrid

Follow-up and Evaluation of the Efficacy of the Hemostatic Treatment in Congenital FVII Deficiency during Development of Inhibitor

Relationship between Molecular Profile and Platelet Function and Thrombin Generation in Patients with Essential Thrombocytemia

Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age

Emicizumab Prophylaxis in Persons with Mild or Moderate Hemophilia A: Results from the Interim Analysis of the HAVEN 6 Study

First Data from the Phase 3 HOPE-B Gene Therapy Trial: Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua hFIX variant; AMT-061) in Adults with Severe or Moderate-Severe Hemophilia B Treated Irrespective of Pre-Existing Anti-Capsid Neutralizing Antibodies

Potential Usefulness of D-Dimers Assay in Treated Patients with FVIII Deficiency to Detect a Prothrombotic State

Real-World Clinical Management of Patients with Congenital Hemophilia and Inhibitors: Interim Analysis of the FEIBA Global Outcome Study (FEIBA GO)

Problem Joints and Their Clinical and Humanistic Burden in Children and Adults with Moderate and Severe Hemophilia a: CHESS Paediatrics and CHESS II

Single 225μg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia Α or Β with Inhibitors: A PERSEPT1 Subset Analysis

In Vitro Evaluation of Thrombin Generation of Eptacog Beta (Factor VIIa, Recombinant) and Emicizumab in Congenital Hemophilia Α Plasma with and without Inhibitors

PERSEPT3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia Α or B with Inhibitors

Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data

Factor VIII gene ( F8 ) mutation and risk of inhibitor development in nonsevere hemophilia A

GPVI Mutation and Absent Platelet Collagen Activation in a Patient with a Bleeding Disorder.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only